The main purpose of this study is to evaluate the safety and efficacy of tirzepatide in adolescents that have obesity with multiple weight related comorbidities.
Age
12–17
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Have body mass index (BMI) equal to or above the 95th percentile for age and sex (on age and gender-specific growth chart for diagnosis of obesity) with at least 2 of the following predefined weight-related comorbidities: hypertension, prediabetes and hypertriglyceridemia.
Have history of at least 1 self-reported unsuccessful dietary effort to lose weight.
Are capable of giving signed informed consent by a legal representative or assent by a study participant (when applicable).
You may not be if
Have undergone or plan to undergo a weight reduction procedure during the study, such as, but not limited to
* gastric bypass
* sleeve gastrectomy
* restrictive bariatric surgery, such as Lap-Band gastric banding, or
* any other procedure intended to result in weight reduction.
Have a self-reported, or by parent or legal guardian where applicable, decrease in body weight greater than 5 kg (11 lbs) within 90 days before screening irrespective of medical records
Have type 1 diabetes or history of ketoacidosis, or hyperosmolar state
Have type 2 diabetes or have a HbA1c \> 6.4% at screening
Have a history of chronic or acute pancreatitis
Have a family or personal history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2
